A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

​ Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: IN10018 in combination with D-1553; Drug: anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed

Sponsors: InxMed (Shanghai) Co., Ltd.

Not yet recruiting Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: IN10018 in combination with D-1553; Drug: anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed
Sponsors: InxMed (Shanghai) Co., Ltd.
Not yet recruiting